Key result
Targeting PANoptosis cell death pathways emerges as a potential therapeutic strategy in atherosclerotic cardiovascular disease.
This review highlights PANoptosis, a novel cell death pathway combining apoptosis, pyroptosis, and necroptosis, as a potential therapeutic target for atherosclerotic cardiovascular diseases.
PANoptosis is a newly discovered cell death pathway triggered by the innate immunizer, which in turn promotes the assembly of the PANoptosome and activates downstream effectors. As a special cell death mode, it is characterized by apoptosis, pyroptosis, and necroptosis at the same time; therefore, it is not feasible to inhibit PANoptosis by suppressing a single cell death pathway. However, active ingredients targeting the PANoptosome can effectively inhibit PANoptosis.Given the importance of cell death in disease, targeting PANoptosis would be an important therapeutic tool. Previous studies have focused more on infectious diseases and cancer, and the role of PANoptosis in the cardiovascular field has not been comprehensively addressed. While ASCVD is the number one killer of cardiovascular diseases, it is important to explore new targets to determine future research directions. Therefore, this review focuses on the assembly of PANoptosome, the molecular mechanism of PANoptosis, and the related mechanisms of PANoptosis leading to ASCVD such as myocardial infarction, ischemic cardiomyopathy and ischemic stroke, in order to provide a new perspective for the prevention and treatment of ASCVD.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). PANoptosis was evaluated. PANoptosis, a cell death pathway involving apoptosis, pyroptosis, and necroptosis, represents a potential novel therapeutic target for the prevention and treatment of atherosclerotic cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: